Abstract: The invention relates to an anti-viral composition comprising at least one, and ideally a plurality of, monoclonal antibodies, or fragments thereof; an immunogenic agent, vaccine or pharmaceutical composition comprising the afore anti-viral composition; said anti-viral composition, immunogenic agent, vaccine or said pharmaceutical composition for use in the treatment of or prevention of a viral infection; use of said anti-viral composition in the manufacture of a medicament to treat or prevent a viral infection; a combination therapeutic for use in the treatment or prevention of a viral infection comprising said anti-viral composition, immunogenic agent, vaccine or pharmaceutical composition in combination with at least one other therapeutic agent; and a method of treating or preventing a viral infection comprising administering said anti-viral composition, immunogenic agent, vaccine or said pharmaceutical composition to an individual having, or suspected of having, a viral infection.

Abstract: There is provided a method for distinguishing between sepsis and systemic inflammatory response syndrome (SIRS) in a patient, comprising: (i) determining the amount of one or more biomarker for sepsis, and one or more biomarker for SIRS in a sample obtained from a patient, wherein the one or more biomarker for sepsis is selected from the group consisting of: ITGB3, ITGA2B, MYL9, LCN2, TREML1, LCN15, CMTM5, PPBP, and PF4; and the one or more biomarker for SIRS is selected from the group consisting of: PLA2G7, ARHGEF10L, MYCL, TGFBI, and GPR124, (ii) comparing the amount of the one or more biomarker for sepsis determined in said sample in (i) to a corresponding reference value representative of a healthy individual, (iii) comparing the amount of the one or more biomarker for SIRS determined in said sample in (i) to a corresponding reference value representative of a healthy individual; wherein the patient is diagnosed as having sepsis, when an increase is observed in the one or more biomarker for sepsis, and no

Abstract: A method for multi-dimensional, relaxation-diffusion magnetic resonance fingerprinting (MRF) includes performing, using a magnetic resonance imaging (MRI) system, a pulse sequence that integrates free-waveform b-tensor diffusion encoding into a magnet resonance fingerprinting pulse sequence to perform a multi-dimensional, relaxation-diffusion encoding while acquiring MRF signal evolutions, processing, using a processor, the acquired MRF signal evolutions to determine at least one relaxation parameter and at least one diffusivity parameter, and generating, using the processor, a report including at least one of the at least one relaxation parameter and the at least diffusivity parameter.

Abstract: The invention concerns a device for introducing microneedles into the skin of a subject; and a method for inserting microneedles into the skin of a subject comprising use of said device.

Abstract: The invention concerns a device for use in ligament surgery to locate the best graft attachment site, including parts thereof; a kit of parts for use in ligament surgery; and a method for performing ligament surgery.

Abstract: Certain aspects of the present disclosure provide techniques for semantically contextualizing structured and unstructured data, extracting and making sense of domain knowledge, and performing semantic-driven optimization to provide generic, scalable, autonomous and real-time performance management within a built environment domain.

Abstract: The present disclosure provides a medical device (100) for inducing cell death in cancer cells. The device comprises a signal generator (102) arranged to generate a pulsed electrical signal, and a transmitter (116) arranged to receive the pulsed electrical signal and generate, in response to the electrical signal, an electric field in a treatment volume. The device (100) is arranged such that the pulsed electrical signal received by the transmitter (116) has a pulse width of 0.1 microsecond to 1 millisecond, and a signal frequency of 10 Megahertz to 20 Gigahertz. The present disclosure also provides a method of inducing cell death. The method comprising a step of generating, using a transmitter (116), a pulsed time varying electric field in a treatment volume comprising a volume of cells to be treated. The electric field has a pulse width of 0.1 microsecond to 1 millisecond, and a signal frequency of 10 Megahertz to 20 Gigahertz.

Abstract: The invention relates to an anti-mitotic agent comprising at least one antibody, or an epitope thereof, that selectively binds the extracellular domain of at least one ZIP (Zrt, Irt-like Proteins) transporter protein to inhibit its function, specifically mitosis; a composition comprising same; and the use of said anti-mitotic agent or composition to treat a hyper proliferative disorder including cancer.

Abstract: The invention concerns a novel acoustofluidic device to separate acoustically active particles from fluids comprising a novel device arrangement for improved acoustic pressure and particle velocity; and a method of separating particles from a fluid comprising use of same.

Abstract: The invention provides compounds of the formula (I): (I) wherein A1, A2, R2, R4, B1, B2, X, X1, n, a and b are as defined are defined in the specification, to pharmaceutical compositions comprising the compounds and the compounds for use as medicaments. The compounds potentiate AMPA receptor function and are expected to be useful in the treatment of central nervous system disorders, for example in the treatment of depressive disorders, mood disorders and cognitive dysfunction associated with neuropsychiatric disorders such as schizophrenia.

Abstract: Microwave resonance cavities and associated methods and apparatus are described. In one example, a cavity (100) comprises a first and a second input port (102, 104) for inputting microwave radiation at a first and a second frequency respectively. The microwave radiation at the first frequency may be to excite a sample in the cavity whereas the microwave radiation at the second frequency may be to interrogate a sample in the cavity for analysis. The cavity has dimensions such that it resonates at both the first and the second frequency.

Abstract: The invention provides compounds of the formula (I): wherein R1 and R2 are defined in the specification, to pharmaceutical compositions comprising the compounds and the compounds for use as medicaments. The compounds potentiate AMPA receptor function and are expected to be useful in the treatment of central nervous system disorders, for example in the treatment of depressive disorders, mood disorders and cognitive dysfunction associated with neuropsychiatric disorders such as schizophrenia.

Abstract: The invention relates to a compound of general formula (I): wherein R1, R2, R3, R4, Q, m and n are as defined herein. The compounds are inhibitors of Bcl-3 and are useful for the treatment of cancer, particularly metastatic cancer.

Abstract: The invention concerns a cartridge for an inhalation device for delivering anaesthetic to a human or animal wherein anaesthetic in said cartridge is dispersed in an anaesthetic control release medium; an inhalation device for use with said cartridge and a formulation comprising at least one selected anaesthetic and anaesthetic control release medium.

Abstract: The present disclosure relates to an immunogenic agent comprising Dna J heat shock protein family (Hsp40) member B7 or an immunogenic fragment thereof; a DNA vaccine comprising a nucleic acid encoding said protein or at least one immunogenic fragment thereof; a pharmaceutical composition or vector or DNA vaccine for use in the treatment of cancer; and a method of treating cancer comprising the use of said immunogenic agent or pharmaceutical composition or vector or DNA vaccine.

Abstract: Methods and apparatus for analysis of nano-objects using wide-field bright field transmission techniques are described. Such methods may comprise acquiring a plurality of images of a sample comprising a plurality of nano-objects using bright field illumination via a continuously variable spectral filter, and identifying a nano-object within the sample in the plurality of images, wherein the position of the nano-object changes between images. Using data extracted from the plurality of images, an extinction cross-section of the identified nano-object may be quantitatively determined.

Abstract: A method of producing at least one compound comprising an alkenyl group from at least one compound comprising an alkyl group having two or more carbon atoms, the method comprising: (i) Providing a mixture comprising carbon dioxide and at least one compound comprising an alkyl group having two or more carbon atoms; and (ii) Contacting said mixture with a catalyst comprising one or both of palladium and platinum and one or more lanthanide, thereby converting at least a portion of the at least one compound comprising an alkyl group having two or more carbon atoms into a compound comprising an alkenyl group, the total of the weight of the palladium and/or platinum being more than 0.1 wt % of the catalyst.

Abstract: In an example, an avalanche photodiode comprises a substrate and a structure comprising a first layer and a second layer, the first and second layers over and parallel to the substrate, wherein the first layer is between the substrate and the second layer. The first layer is an Aluminium Arsenide Antimonide multiplication layer, and wherein the cross-sectional area parallel to the substrate of the first layer is smaller than that of the second layer, thereby forming a recess in a sidewall of the structure.

Abstract: Sepsis remains a leading cause of morbidity and mortality in neonates worldwide. There is also clinically a low threshold for suspicion of infection in neonates, in particular as presentation varies greatly from very subtle to catastrophic collapse. The lack of reliably sensitive tests and the potential life-threatening consequences of delayed treatment of infection results in the widespread use of empirical antibiotics exposing many infants without infection to broad-spectrum antibiotics. The present invention provides a series of patient-invariant biomarkers for screening neonates and other subjects for infection that predicts bacterial infection with high accuracy; and is further shown to have predictive value in identifying infection in suspected cases with blood-culture negative tests.

Abstract: The invention relates to a high throughput method for determining telomere length of mammalian chromosomal DNA; primers for use in said method; a kit comprising said primers; use of said method to diagnose or prognose or to determine the risk of developing a telomere shortening disease such as cancer, ageing, neurological disorders including Alzheimer's disease, Parkinson's disease and other dementias, brain infarction, heart disease, chronic HIV infection, chronic hepatitis, skin diseases, chronic inflammatory bowel disease including ulcerative colitis, anaemia, atherosclerosis, Barrett's oesophagus and cancers including pre-cancerous conditions, infertility, telomere syndromes including dyskeratosis congenita, aplastic anaemia, idiopathic pulmonary fibrosis, familial myelodysplastic syndrome-acute myeloid leukaemia, Hoyeraal-Hreiderasson syndrome, Revesz syndrome, Coats plus syndrome, bone marrow failure, and cryptogenic liver cirrhosis.